KPV | 10 MG

KPV is a synthetic tripeptide (Lys-Pro-Val, often as Ac-KPV-NH₂) derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). It is a research compound valued for its potent anti-inflammatory, immune-modulating, and tissue-protective properties, studied primarily in preclinical models and limited human cell/tissue research for its ability to regulate inflammatory pathways without broad immunosuppressive effects.

KPV is thought to work by:

• Inhibiting NF-κB activation and nuclear translocation of pro-inflammatory signals
• Reducing cytokine production (e.g., TNF-α, IL-8)
• Supporting mucosal barrier integrity and wound healing
• Modulating immune responses in epithelial cells, macrophages, and other tissues

Potential human benefits (drawn from preclinical animal models showing strong effects in colitis/inflammation, small human cell studies, and widespread anecdotal reports in wellness, gut health, dermatology, and regenerative communities):

• Gut health and inflammatory bowel support — promotes reduced intestinal inflammation, preserved gut lining, faster mucosal healing, and balanced microbiome in models of colitis, IBD, or leaky gut; users often report eased digestive discomfort, better tolerance to foods, and symptom relief.
• Anti-inflammatory effects — calms systemic or localized inflammation, potentially aiding conditions like joint issues, skin flare-ups, or chronic low-grade inflammation with fewer side effects than traditional agents.
• Skin healing and dermatological benefits — accelerates wound closure, reduces redness/swelling, and supports repair in models of dermatitis, psoriasis, eczema, or acne; topical forms are popular for clearer, calmer skin.
• Immune balance and antimicrobial hints — helps modulate immune responses without suppression, with some preclinical antimicrobial activity and protection against infection during healing.
• General regenerative perks — anecdotal accounts frequently highlight faster tissue recovery, reduced pain/swelling in injuries or post-procedure, and overall resilience against inflammatory stressors.

Human evidence remains limited to small pilots, cell-based studies, and observations (e.g., reduced inflammatory markers in airway/gut epithelium, efficacy in animal colitis models via oral/topical delivery), with no large-scale randomized controlled trials confirming broad clinical use. Benefits are often described as targeted, cumulative, and synergistic with lifestyle or other therapies.

Important Notice:

This product is intended for research use only.
Not for human or animal use of any kind.
Not a drug. Not approved for clinical or therapeutic use.

This product is intended for research use only.
Not for human or animal use of any kind.
Not a drug. Not approved for clinical or therapeutic use.